| OTSUKA PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20160136916 | METHOD AND APPARATUS FOR MANUFACTURING NUCLEATED TABLETS (AS AMENDED) - Provided is a method and apparatus for manufacturing nucleated tablets in each of which a nucleus is positioned in a precise manner. In the tablet manufacturing machine ( | 05-19-2016 |
| 20160130586 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. | 05-12-2016 |
| 20160101183 | AQUEOUS OPHTHALMIC SUSPENSION OF CRYSTALLINE REBAMIPIDE - The invention provides an ophthalmic product containing rebamipide, which has a transparency enough to be agreeable feeling on using it and has neutral so weakly acidic pH not to injury of the keratoconjunctiva of a patient suffering from dry eye. An aqueous suspension of crystalline rebamipide which has an improved transparency is provided by adding an aqueous solution of rebamipide dissolved by a base such as sodium hydroxide or an aqueous solution of a salt of rebamipide to an aqueous acidic solution such as hydrochloric acid containing at least one of the compounds selected from water-soluble polymers and surfactants, and mixing them. | 04-14-2016 |
| 20160083458 | ANTI-LIPOARABINOMANNAN ANTIBODY AND IMMUNOASSAY FOR ACID-FAST BACILLARY INFECTION USING THE ANTIBODY - The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below:
| 03-24-2016 |
| 20160058841 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 03-03-2016 |
| 20160051548 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 02-25-2016 |
| 20160000801 | SUSPENSION FOR ORAL ADMINISTRATION COMPRISING AMORPHOUS TOLVAPTAN - This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. | 01-07-2016 |
| 20150374730 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 12-31-2015 |
| 20150366859 | SOLID DISPERSION COMPRISING AMORPHOUS CILOSTAZOL - The present invention relates to a solid dispersion comprising cilostazol, and methacrylic acid copolymer S and/or methacrylic acid copolymer L, which is characterized in that cilostazol is retained in an amorphous state in a gastrointestinal tract for a certain period after oral administration. | 12-24-2015 |
| 20150352095 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 12-10-2015 |
| 20150322534 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 11-12-2015 |
| 20150299748 | FERMENTATION PRODUCT CONTAINING EQUOL-PRODUCING MICROORGANISM HAVING MAINTAINED EQUOL-PRODUCING ABILITY, AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained. | 10-22-2015 |
| 20150297694 | CANCER DIAGNOSTIC AND THERAPEUTIC METHOD TARGETING MOLECULES EXPRESSED IN CANCER STEM CELLS - The present invention provides a novel method for determining cancer malignancy, a novel cancer diagnostic method, a novel method for determining prognosis, a novel vaccine for cancer treatment, and a novel vaccine for suppressing cancer metastasis. Specifically, the invention provides a cancer malignancy evaluation method that comprises the step of measuring a DDX3X expression level in a cancer tissue, and the step of evaluating malignancy of the cancer tissue by using the DDX3X expression level. | 10-22-2015 |
| 20150272946 | Prophylactic and/or Therapeutic Agent for Behavioral And Psychological Symptoms Associated With Neurodegenerative Disease or Impulsive Symptoms Associated With Mental Disease Containing Brexpiprazole or Salt Thereof - The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient. | 10-01-2015 |
| 20150246032 | PHARMACEUTICAL COMPOSITION COMPRISING REBAMIPIDE - The present invention relates to a rebamipide-containing ophthalmic composition which achieves a superior re-dispersibility and transparency by comprising various additives as well as a zinc compound as a preservative (which supplements the antiseptic-effect) in the amount which does not produce an adverse effect. | 09-03-2015 |
| 20150240275 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS - An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. | 08-27-2015 |
| 20150218101 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 08-06-2015 |
| 20150216766 | SUNSCREEN COMPOSITION - The present invention provides a sunscreen composition comprising two or more oil-soluble ultraviolet absorbers and composite silicone particles having an average particle diameter of 10 μm or less. | 08-06-2015 |
| 20150215996 | MICROWAVE HEATING DEVICE AND FIRING FACILITY - A microwave heating device which enables use of a conveyor with a metallic belt is provided, as is a baking facility having the device. The device includes a conveying means for conveying objects to be heated; a microwave generating means for emitting microwaves to the objects to be heated conveyed by the conveying means; a rotating member that is provided between the objects to be heated and the microwave generating means, and that has a rotary vane configured to reflect the microwaves emitted from the microwave generating means; and a shielding member configured to reflect the microwaves, provided between the rotating member and the objects to be heated. The conveying means has a metallic holding member for holding the objects to be heated, and the shielding member has a microwave transmitting unit for transmitting the microwaves. The microwave transmitting unit extends in a direction orthogonal to the conveyance direction of the objects to be heated conveyed by the conveying means. | 07-30-2015 |
| 20150203698 | TABLET HAVING DRY-INK FILM ON SURFACE THEREOF, AND INK FOR INKJET PRINTER - The invention provides a tablet having a powdered or soft surface on which a dry-ink film of information for improving identifiability of the tablet is printed, and provides an ink for inkjet printers. | 07-23-2015 |
| 20150184252 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 07-02-2015 |
| 20150176083 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 06-25-2015 |
| 20150150806 | METHOD FOR PRODUCING MATRIX-TYPE PHARMACEUTICAL SOLID PREPARATION - The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a method for producing a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; (b) a sugar and/or a sugar alcohol, and (c) tolvaptan. | 06-04-2015 |
| 20150141338 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 05-21-2015 |
| 20150105432 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER - The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R | 04-16-2015 |
| 20150087654 | METHOD OF PROVIDING ARIPIPRAZOLE TO PATIENTS HAVING IMPAIRED CYP2D6 OR CYP3A4 ENZYME FUNCTION - The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both. | 03-26-2015 |
| 20150082752 | SEALING DEVICE AND SEALING METHOD - An object of the present invention is to provide a sealing device and a sealing method with which oxygen substitution can be sufficiently carried out even in a bag-like container. The present invention is a sealing device for putting a content into a bag-like container and sealing the container, and includes a content supply portion that supplies the content to the container having an opening in an open state, an inert gas supply portion that supplies inert gas to the container, a liquefied inert gas supply portion that supplies liquefied inert gas to the container, and a sealing portion that seals the opening of the container after the liquefied inert gas is supplied. | 03-26-2015 |
| 20150064237 | MEDICINAL COMPOSITION FOR TREATING INFARCTION - The present invention provides a pharmaceutical composition for treating infarction, such as myocardial infarction or cerebral infarction, with a method that is different from conventional therapeutic methods that use a thrombolytic agent or balloon therapy. | 03-05-2015 |
| 20150045356 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS - Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof. | 02-12-2015 |
| 20150037424 | SUSTAINED RELEASE ORAL SOLID PREPARATION - Provided is a sustained release oral solid preparation comprising aripiprazole or a salt thereof as an active ingredient described below, and a method for producing the sustained release oral solid preparation. | 02-05-2015 |
| 20150024056 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 01-22-2015 |
| 20140377765 | METHOD FOR DETERMINING SEVERITY OF PNEUMOCOCCAL PNEUMONIA - Provided is a method that can more objectively and rapidly determine severity of pneumococcal pneumonia using blood of a subject. The method determines severity of pneumococcal pneumonia, the method including determining the severity based on the presence or absence of a pneumococcal antigen in blood collected from a subject and at least one biochemical value selected from a blood C-reactive protein (CRP) level, a white blood cell (WBC) count and a blood urea nitrogen (BUN) level. | 12-25-2014 |
| 20140315986 | APTAMERS THAT BIND TO IL-6 AND THEIR USE IN TREATING OR DIAGNOSING IL-6 MEDIATED CONDITIONS - Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided. | 10-23-2014 |
| 20140315886 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Methods of treating disorders using compounds (I) that modulate stri-atal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I). | 10-23-2014 |
| 20140315264 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS - An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. | 10-23-2014 |
| 20140309236 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period. | 10-16-2014 |
| 20140288151 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. | 09-25-2014 |
| 20140288065 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 09-25-2014 |
| 20140234417 | TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF - This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]- | 08-21-2014 |
| 20140221469 | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use. | 08-07-2014 |
| 20140221388 | CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS - The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder. | 08-07-2014 |
| 20140194765 | Method of Exhaled Gas Measurement and Analysis and Apparatus Therefor - An exhalation collected in a breath bag capable of expanding and contracting is sucked into a gas inlet vessel | 07-10-2014 |
| 20140194621 | PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2, 4-DIONE COMPOUND - A process for producing a compound represented by formula (1), | 07-10-2014 |
| 20140187782 | METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND - The present invention provides a method for producing a compound of Formula (4): wherein R | 07-03-2014 |
| 20140186826 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 07-03-2014 |
| 20140179675 | QUINOLONE COMPOUND - The present invention provides a compound represented by the formula (I) | 06-26-2014 |
| 20140178464 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 06-26-2014 |
| 20140163039 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 06-12-2014 |
| 20140145082 | DRUG INSPECTION DEVICE AND DRUG INSPECTION METHOD - A drug inspection device and method for distinguishing tablets that have different amounts of active pharmaceutical ingredients and are indistinguishable in appearance. The device focuses on a tablet packaging process for tablets containing different amounts of active pharmaceutical ingredients, every row or every pocket, having housed therein a plurality of tablets, is used for conveyance. A beam having near-infrared light irradiates the tablets, a spectroscope receives reflected light, a near-infrared imaging unit captures a spectrum obtained through dispersion of the reflected light by the spectroscope and generates image data, and a control unit processes the image data and performs an operation for distinguishing the types of tablets. The control unit controls the near-infrared imaging unit to perform image capture at least once on the tablets included in the one row, to compute average spectrum data per tablet, and to distinguish the type of tablet based on the average spectrum data. | 05-29-2014 |
| 20140121207 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 05-01-2014 |
| 20140117239 | DRUG DETECTION DEVICE AND DRUG DETECTION METHOD - Provided are a drug detection device and a drug detection method that are able to compute the residual amount of a drug quickly and in a contactless manner. The drug detection device according to the present invention is for detecting a drug remaining in a target area, and includes an irradiation unit configured to irradiate a target area with a light beam including near-infrared light, a spectroscope on which reflected light from the target area is incident, a near-infrared imaging unit configured to capture a spectrum obtained through dispersion of the reflected light by the spectroscope and to generate image data, a control unit configured to process the image data, and a storage unit configured to store an equation expressing a relationship between a prescribed amount of a drug and spectral data that is based on the spectrum. The near-infrared imaging unit is configured to capture each spectrum of a predetermined number of pixels allocated within the target area, and the control unit is configured to compute average spectral data of the area by averaging the spectrums of the pixels, and to compute an amount of the drug corresponding to the average spectral data, based on the equation stored in the storage unit. | 05-01-2014 |
| 20140113937 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 04-24-2014 |
| 20140105968 | TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG ARRIVAL - An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. | 04-17-2014 |
| 20140100226 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: | 04-10-2014 |
| 20140086514 | Packaging Bag and Method of Producing the Same - Provided is a packaging bag including a notch being formed in the edge seal portion, the notch serving as a starting point for opening of the bag body, and an easy-to-cut portion disposed on an extension of the notch in an opening direction. The easy-to-cut portion is formed to extend beyond the back seal portion between one side and the other side of the back seal portion, and the ends of the easy-to-cut portion are disposed away from side ends of the bag body, respectively. | 03-27-2014 |
| 20140072985 | Bioassay Method for Antibody Against Thyroid-Stimulating Hormone Receptor, Measurement Kit for the Antibody, and Novel Genetically Modified Cell for Use in the Bioassay Method or the Measurement Kit - The present invention provides a method and a kit for assaying a TSH receptor antibody, which are easy to manipulate and are safe. Specifically, the present invention provides a composition comprising a genetically modified cell forced to co-express a TSH receptor, a cyclic nucleotide responsive calcium channel, and a luminescent protein aequorin. Use of the composition enables the assay of a TSH receptor antibody contained in a sample. | 03-13-2014 |
| 20140065076 | CONTAINER WITH CONCENTRATED SUBSTANCE AND METHOD OF USING THE SAME - Apparatus and methods are described herein for a container with a unit dose of a concentrated substance that can be diluted and orally consumed using the container. In some embodiments, an apparatus includes a container body that defines an opening in fluid communication with an interior of the container body. A cap is coupled to the container body and encloses the opening. A unit dose of a concentrated medicament or a concentrated contrast agent is disposed within the interior of the container body. The unit dose of concentrated medicament or contrast agent can be diluted to a select dilution strength with a volume of a liquid receivable through the opening and within the interior of the container body. In some embodiments, the apparatus can include a barrier member in which the container body and cap can be disposed to protect the medicament or contrast agent from light and/or moisture. | 03-06-2014 |
| 20140050703 | EQUOL-PRODUCING LACTIC ACID BACTERIA-CONTAINING COMPOSITION - An equol-producing lactic acid bacteria-containing composition comprises, as an essential component thereof, a lactic acid bacterial strain belonging to the genus | 02-20-2014 |
| 20140045889 | Combination Drug Containing Probucol and a Tetrazolyalkoxy-Dihydrocarbostyril Derivative With Superoxide Supressant Effects - This invention relates to a combination drug comprising a combination of a tetrazolylalkoxy-dihydrocarbostyril derivative of the formula: | 02-13-2014 |
| 20140045793 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): | 02-13-2014 |
| 20140031342 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES - The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): | 01-30-2014 |
| 20140031334 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS - A heterocyclic compound or a salt thereof represented by the formula (1): | 01-30-2014 |
| 20140030523 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period. | 01-30-2014 |
| 20140024640 | Benzazepine Derivatives Useful as Vasopressin Antagonists - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 01-23-2014 |
| 20140024619 | Benzazepine Derivatives Useful as Vasopressin Antagonists - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 01-23-2014 |
| 20140018369 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 01-16-2014 |
| 20140017217 | AGENT FOR IMPROVING OR MAINTAINING QOL - An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. | 01-16-2014 |
| 20130345133 | Adiponectin for Treating Pulmonary Disease - The present invention provides an agent for inhibiting alveolar airspace enlargement containing adiponectin or an agent for inhibiting alveolar wall destruction containing adiponectin. The pulmonary disease therapeutic agents of the present invention are highly safe drugs that possess an excellent effect of decreasing the deterioration of the pulmonary function, such as airflow limitation, and exhibit an extremely high effect of treating pulmonary disease accompanied by irreversible deterioration in pulmonary function, with fewer adverse side effects such as nausea, vomiting and gastric acid secretion. | 12-26-2013 |
| 20130331358 | Water-Soluble Benzoazepine Compound and Its Pharmaceutical Composition - The present invention provides a benzoazepine compound represented by following general formula (1): | 12-12-2013 |
| 20130302384 | MEDICAL DEVICE CONTAINING A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT, AND A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT - The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient. The present invention relates to a medical device containing, in a storage container whose inner wall is treated with silicone, a freeze-dried cake composition comprising separately prepared aripiprazole as an active ingredient, wherein there is a space between the inner wall and the cake composition; and a cake composition comprising aripiprazole as an active ingredient and having a strength of 5 to 100 N. | 11-14-2013 |
| 20130296336 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 11-07-2013 |
| 20130266958 | METHOD FOR ACTIVATING HELPER T CELL - The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1* 0101 molecule, an HLA-DRB1* 0401 molecule, an HLA-DRB1* 0403 molecule, an HLA-DRB1* 0406 molecule, an HLA-DRB1* 0803 molecule, an HLA-DRB1* 0901 molecule, an HLA-DRB1* 1101 molecule, an HLA-DRB3* 0202 molecule, an HLA-DRB4* 0101 molecule, an HLA-DPB1* 0201 molecule or an HLA-DPB1* 0301 molecule, and the like. | 10-10-2013 |
| 20130245239 | PROTEOGLYCAN-BONDED FIBER PRODUCT AND METHOD OF MANUFACTURING SAME - An objective is to provide fiber products having smooth texture and excellent softness, and in addition, excellent durability. A proteoglycan-bonded fiber product including a fiber to which a proteoglycan is covalently bonded is provided. | 09-19-2013 |
| 20130217754 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS - Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1. | 08-22-2013 |
| 20130217678 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND - The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): | 08-22-2013 |
| 20130216680 | HOLLOW CONFECTIONERY AND METHOD FOR PRODUCING THE SAME - This invention provides a food product that allows intake of all of the nutritional components of soybeans, has no smell of raw soybeans, has good flavor, is easy to eat, can increase the soybean content, and can be eaten by children and adults. Provided is a hollow confectionery obtained by baking dough comprising soybeans, a starch, and a pregelatinized starch. | 08-22-2013 |
| 20130216491 | COMPOSITION FOR CLEANING SCALP AND HEAD HAIR - This invention provides a cleaning composition comprising a certain amount or more of an acylamino acid type surfactant, and further a non-ionic surfactant and a betaine-type ampholytic surfactant, which has a sufficient viscosity and exerts excellent conditioning effects. | 08-22-2013 |
| 20130203750 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 08-08-2013 |
| 20130184312 | Tetomilast Polymorphs - The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a power X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. | 07-18-2013 |
| 20130158044 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 06-20-2013 |
| 20130150568 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS - An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. | 06-13-2013 |
| 20130143250 | CYCLIC NUCLEOTIDE-SPECIFIC PHOSPHODIESTERASES FROM LEISHMANIA AND USES THEREOF - The present invention relates to novel amino acid and nucleic acid sequences of yclic nucleotide-specific phosphodiesterases from the parasite | 06-06-2013 |
| 20130136846 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD - The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same.
| 05-30-2013 |
| 20130131045 | BENZAZEPINE COMPOUND - An object of the present invention is to provide a novel benzazepine compound or a salt thereof, which has excellent vasopressin antagonistic activity. | 05-23-2013 |
| 20130090301 | AGENT FOR SUPPRESSING THE FORMATION OF ABNORMAL SKIN CELLS CAUSED BY EXPOSURE TO LIGHT - An object of the present invention is to provide an agent for suppressing the formation of skin cells induced by exposure to light such as ultraviolet light. The object is achieved by using a purine nucleic acid for suppressing the formation of abnormal skin cells caused by exposure to light. | 04-11-2013 |
| 20130072683 | EPOXY COMPOUND AND METHOD FOR MANUFACTURING THE SAME - The present invention provides a novel intermediate for manufacturing a 2,3-dihydroimidazo[2,1-b]oxazole compound with a high yield and a high purity, and a manufacturing method of the intermediate. The present invention provides an epoxy compound represented by the general formula (2): wherein, R1 represents a hydrogen or a lower alkyl group; and R2 represents a piperidyl group represented by the general formula (A1): (wherein, R3 represents a phenoxy group having a halogen-substituted lower alkoxy group substituted on a phenyl group, and the like) and the like; and n represents an integer of 1 to 6, a manufacturing method of the epoxy compound, and a manufacturing method of an oxazole compound using the epoxy method. | 03-21-2013 |
| 20130066085 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD - The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. | 03-14-2013 |
| 20130066084 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD - The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. | 03-14-2013 |
| 20130045250 | SUSPENSION AND CAKE COMPOSITION CONTAINING CARBOSTYRYL DERIVATIVE AND SILICONE OIL AND/OR SILICONE OIL DERIVATIVE - A suspension and a cake composition are provided in which agglomeration of the active ingredient that is caused when silicone oil and/or silicone oil derivative is contained therein can be suppressed without a special treatment, such as sonication. The suspension contains, in a dispersion medium, an active ingredient of a specific mean primary particle size, and silicone oil and/or silicone oil derivative. The cake composition contains an active ingredient of a specific mean particle size, and silicone oil and/or silicone oil derivative. | 02-21-2013 |
| 20130040941 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a novel benzodiazepine compound that blocks the I | 02-14-2013 |
| 20130029013 | BOTTLED CARBONATED BEVERAGE CONTAINING SOYBEAN POWDER OR SOY MILK | 01-31-2013 |
| 20130023429 | TRANSCRIPTION CHIP - A transcription chip comprising a substrate and, immobilized thereon, at least one polynucleotide including an element sequence to which a transcription factor can be bound. | 01-24-2013 |
| 20130022637 | RECOMBINANT BACULOVIRUS VACCINE - The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients. | 01-24-2013 |
| 20130017221 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 01-17-2013 |
| 20130012882 | PROTEOGLYCAN-CONTAINING MICRONEEDLE ARRAY - An object of the present invention is to provide a novel microneedle array that has ( | 01-10-2013 |
| 20130012693 | Aptamers to Beta-NGF and Their Use in Treating Beta-NGF Mediated Diseases and Disorders - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to β-NGF; pharmaceutical compositions comprising such β-NGF aptamers; and methods of making and using the same. | 01-10-2013 |
| 20130005675 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): | 01-03-2013 |
| 20130004647 | PROCESSED SOYBEAN HAVING REDUCED UREASE CONTENT AND MANUFACTURING METHOD OF THE SAME - This invention relates to a processed soybean having a reduced urease content, the soybean being produced by decompressing and steaming. | 01-03-2013 |
| 20120322807 | STAT3/5 ACTIVATION INHIBITOR - The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: | 12-20-2012 |
| 20120316180 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 12-13-2012 |
| 20120316179 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 12-13-2012 |
| 20120316168 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 12-13-2012 |
| 20120315302 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 12-13-2012 |
| 20120302757 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a method for producing an oxazole compound in a high yield. | 11-29-2012 |
| 20120277303 | EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 11-01-2012 |
| 20120277302 | EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 11-01-2012 |
| 20120258971 | THERAPEUTIC AGENT FOR CHRONIC PAIN - This invention provides a novel therapeutic agent for chronic pain. The therapeutic agent for chronic pain comprises aripiprazole as an active ingredient. | 10-11-2012 |
| 20120225866 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION - The present invention provides a novel diazepine compound that blocks the I | 09-06-2012 |
| 20120165401 | APTAMER FOR CHYMASE, AND USE THEREOF - Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X | 06-28-2012 |
| 20120157663 | ANTIBODY IDENTIFYING AN ANTIGEN-BOUND ANTIBODY AND AN ANTIGEN-UNBOUND ANTIBODY, AND METHOD FOR PREPARING THE SAME - The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody. | 06-21-2012 |
| 20120149899 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND - The present invention provides an industrially advantageous, simple, and efficient process for producing a key intermediate of a benzo[b][1,4]diazepine-2,4-dione compound, which is a therapeutic medicine for arrhythmia. | 06-14-2012 |
| 20120128857 | CARBONATED DRINK COMPRISING SOYBEAN FLOUR OR SOYBEAN MILK - An object of the present invention is to provide a carbonated beverage containing soybean powder or soymilk, wherein the carbonated beverage is provided with a refreshing carbonic acid flavor as well as nutrients and good flavor derived from soybeans, and the soybean-derived ingredient is stably maintained without becoming coagulated even when the content of the soybean-derived ingredient is high. | 05-24-2012 |
| 20120122245 | ALLOYED METAL COLLOID - Provided is a metal colloid having higher visibility and higher sensitivity than a gold colloid and a Au-core Pt-shell composite colloid and suitable as a labeling agent for use in a test such as an immunoassay. An alloyed Au/Pt composite colloid formed by mixing a gold salt and a platinum salt with at least one reducing agent selected from the group consisting of an amino acid and a derivative thereof, an oligopeptide and a derivative thereof, and an amino sugar in the presence of an alkali, thereby reducing the gold salt and platinum salt. | 05-17-2012 |
| 20120100190 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 04-26-2012 |
| 20120065162 | N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1) | 03-15-2012 |
| 20120064550 | METHOD FOR MEASUREMENT OF EQUOL IN BIOLOGICAL SAMPLE BY IMMUNOASSAY, KIT FOR THE MEASUREMENT, AND METHOD FOR DETERMINATION OF EQUOL PRODUCTION ABILITY OF SUBJECT - An object of the present invention is to provide a method for measuring equol in a biological sample by an immunological method, a kit for the measurement, and a method for determining equol-producing ability of a subject. | 03-15-2012 |
| 20120015025 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. | 01-19-2012 |
| 20120009251 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 01-12-2012 |
| 20120004186 | PLATELET AGGREGATION INHIBITOR COMPOSITION - The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): | 01-05-2012 |
| 20110294143 | METHOD FOR DETECTING ALL HAEMOPHILUS INFLUENZAE - Provided is an immunoassay method whereby all | 12-01-2011 |
| 20110281819 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME - A low-molecular-weight polysulfated hyaluronic acid derivative useful for prevention and/or treatment of an allergic disease. An agent for prevention and/or treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); | 11-17-2011 |
| 20110281284 | NOVEL LIVER CANCER MARKER - According to the present invention, HDGF in the blood of patients with chronic liver disease is measured to diagnose whether the patients have liver cancer. A measurement kit for the diagnosis is also provided. | 11-17-2011 |
| 20110269705 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): | 11-03-2011 |
| 20110251180 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND - The present invention provides a pharmaceutical agent that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the pharmaceutical agent of the invention comprising as an active ingredient a quinolone compound represented by Formula (1): | 10-13-2011 |
| 20110207911 | POLYPEPTIDE DERIVED FROM THE RYANODINE RECEPTOR THAT INHIBITS CALCIUM LEAKAGE - A polypeptide exhibiting the effect of inhibiting Ca | 08-25-2011 |
| 20110201086 | METHOD FOR PRODUCING RECOMBINANT VIRUS - To provide a method for producing, at high purity, a recombinant baculovirus which exhibits intended immunogenicity and is useful for a pharmaceutical (e.g., a vaccine), a transfer vector for use in the production of the recombinant baculovirus, and a method for producing the transfer vector. The method for producing a transfer vector which includes therein a fusion gene containing at least one gene encoding a virus-particle-forming protein and a gene encoding a foreign immunogenic protein, the method including modifying the polynucleotide sequence of the gene encoding the virus-particle-forming protein so as not to alter the amino acid residues constituting a corresponding naturally occurring virus-particle-forming protein and/or modifying the polynucleotide sequence of the gene so that a portion of the amino acid residues constituting the naturally occurring virus-particle-forming protein is deleted. | 08-18-2011 |
| 20110200712 | LOW-CALORIE BEVERAGE COMPOSITION CONTAINING LUO HAN GUO EXTRACT AND SUCRALOSE - An object of the present invention is to provide a low-calorie drink composition having a refreshing sweet taste, the composition being free of bitter taste, salty taste, astringent taste or the like that inorganic electrolyte-containing drinks generally have. | 08-18-2011 |
| 20110189134 | FERMENTATION PRODUCT CONTAINING EQUOL-PRODUCING MICROORGANISM HAVING MAINTAINED EQUOL-PRODUCING ABILITY, AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a fermented product containing equol-producing microorganisms in the state of living cells by which equol production ability is maintained. | 08-04-2011 |
| 20110165249 | PHARMACEUTICAL SOLID PREPARATION - An object of the present invention is to provide a gradual disintegration-type, sustained-release pharmaceutical solid preparation whose pharmacologically active substance release behavior is controlled. The solid pharmaceutical preparation of the present invention is a matrix-type preparation containing: (a) a pharmacologically active substance; (b) calcium polycarbophil; and (c) a specific sugar and/or sugar alcohol. | 07-07-2011 |
| 20110150847 | METHOD OF THREE-DIMENSIONALLY CULTURING CHONDROCYTES - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue. | 06-23-2011 |
| 20110105718 | NEL-RELATED PROTEIN TYPE 1 ANTIBODY - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 05-05-2011 |
| 20110067696 | POWDER INHALER - An object of the present invention is to provide a powder inhaler that does not require shaking, and that therefore can be operated in an efficient manner. | 03-24-2011 |
| 20110045491 | CYCLIC NUCLEOTIDE-SPECIFIC PHOSPHODIESTERASES FROM LEISHMANIA AND USES THEREOF - The present invention, relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite | 02-24-2011 |
| 20110038958 | USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT - The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication. | 02-17-2011 |
| 20110034545 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT - An object of the present invention is to provide a novel double-stranded RNA that has high resistance to nuclease and cellular uptake efficiency and that can produce an excellent RNA interference effect. The present invention provides a double-stranded lipid-modified RNA comprising a sense strand having a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand having a nucleotide sequence complementary to the sense strand, the double-stranded RNA being capable of suppressing the expression of the target gene, and the sense strand having a double-stranded lipid bound directly or via a linker to at least one of the first to sixth nucleotides from the 5′ end. | 02-10-2011 |
| 20110033564 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD - The present invention relates to an extract obtained by extracting useful components containing equol from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. | 02-10-2011 |
| 20110020848 | METHOD FOR DETECTION OF PNEUMOCOCCUS - To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody. | 01-27-2011 |
| 20100331423 | AQUEOUS SOLUTION OF OLANEXIDINE, METHOD OF PREPARING THE AQUEOUS SOLUTION, AND DISINFECTANT - The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a disinfectant containing an aqueous solution that contains olanexidine and at least an equimolar amount of gluconic acid, and substantially contains neither an acid other than gluconic acid nor a salt of the acid other than gluconic acid. | 12-30-2010 |
| 20100331421 | DISINFECTANT AND/OR BACTERICIDAL AQUEOUS COMPOSITIONS - The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin. | 12-30-2010 |
| 20100330627 | ENZYME ASSOCIATED WITH EQUOL SYNTHESIS - An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. | 12-30-2010 |
| 20100323006 | PHARMACEUTICAL SOLID PREPARATION COMPRISING BENZAZEPINES AND PRODUCTION METHOD THEREOF - The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises:
| 12-23-2010 |
| 20100305190 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION - The present invention provides a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid to be introduced into a cell, and a highly branched cyclic dextrin. Moreover, when a carrier comprising (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine is used as a nucleic acid delivery carrier to introduce the nucleic acid complex into a cell, the safety, the efficiency of intracellular delivery, and the persistence of the nucleic acid in the cell can be further improved. | 12-02-2010 |
| 20100298411 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT - An object of the present invention is to provide a novel double-stranded RNA that has high nuclease resistance and high cellular uptake efficiency, and that is capable of producing an excellent RNA interference effect. The present invention provides a lipid-modified double-stranded RNA comprising a sense strand having a nucleotide sequence complementary to a target sequence, and an antisense strand having a nucleotide sequence complementary to the sense strand, the double-stranded RNA being capable of inhibiting the expression of the target gene, the sense strand having a lipid linked to at least one of the first to sixth nucleotides from the 5′ end side directly or via a linker. | 11-25-2010 |
| 20100292176 | ANTITUMOR AGENT - Provided is a sugar-cholestanol compound which can be readily synthesized, and which exhibits a satisfactory antitumor activity. | 11-18-2010 |
| 20100285499 | HUMAN p51 GENES AND GENE PRODUCTS THEREOF - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 11-11-2010 |
| 20100273176 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100273175 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100261880 | LY6H POLYPEPTIDE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 10-14-2010 |
| 20100261720 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides a heterocyclic compound represented by General Formula (1): | 10-14-2010 |
| 20100249104 | METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL - The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration. | 09-30-2010 |
| 20100210661 | STAT3/5 ACTIVATION INHIBITOR - An object of the present invention is to provide a STAT3/5 activation inhibitor. The present invention provides a STAT3/5 activation inhibitor containing an aromatic compound represented by the general formula or a salt thereof as an active ingredient: | 08-19-2010 |
| 20100203151 | MICROSPHERES HAVING CORE/SHELL STRUCTURE - Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like. | 08-12-2010 |
| 20100192946 | METERED DOSE INHALER - The present invention provides an improved metered dose inhaler utilizing the property of the aerosol canister. The metered dose inhaler includes: a housing body ( | 08-05-2010 |
| 20100167321 | EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402. | 07-01-2010 |
| 20100160611 | HUMAN SKELETAL MUSCLE-SPECIFIC UBIQUITIN-CONJUGATING ENZYME - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 06-24-2010 |
| 20100159072 | Fermented Tea Beverage and Tea Beverage - The present invention provides a tea-based fermentation beverage comprising a tea-based fermentation liquid with at least one species of lactic acid bacteria selected from the group consisting of | 06-24-2010 |
| 20100137407 | SINGLE-CHAIN CIRCULAR RNA AND METHOD OF PRODUCING THE SAME - The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem. | 06-03-2010 |
| 20100130546 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 05-27-2010 |
| 20100130508 | PHARMACEUTICAL COMPOSITION COMPRISING 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE DERIVATIVES - A pharmaceutical composition according to the present invention comprises: (I) at least one member selected from the group consisting of oxazole compounds, optically active isomers thereof, and salts thereof, the oxazole compounds being represented by general formula (1): wherein R | 05-27-2010 |
| 20100104595 | LYOPHILIZED PREPARATION COMPRISING INFLUENZA VACCINE, AND METHOD FOR PREPARATION THEREOF - The present invention aims to provide a freeze-dried preparation in which the influenza vaccine exhibits improved stability. | 04-29-2010 |
| 20100063131 | PROMPT NUCLEIC ACID DELIVERY CARRIER COMPOSITION - An object of the present invention is to provide a carrier composition for nucleic acid delivery, which can efficiently deliver a nucleic acid into cells when a nucleic acid such as siRNA is administered to animal-derived cells or animals, and also has low toxicity and high safety, and a composition for nucleic acid delivery containing the carrier composition and nucleic acid. | 03-11-2010 |
| 20100062053 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 03-11-2010 |
| 20100048878 | HUMAN GENE - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases. | 02-25-2010 |
| 20090311353 | EQUAL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 12-17-2009 |
| 20090258923 | Carrier Composition for Nucleic Acid Transport - An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. | 10-15-2009 |
| 20090221586 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: | 09-03-2009 |
| 20090205656 | POWDER INHALER - The subject invention provides a powder inhaler enabling the user to complete powder drug inhalation with fewer steps, for improved user convenience. | 08-20-2009 |
| 20090162291 | MAGNETIC RESONANCE CONTRAST MEDIUM USING POLYETHYLENE GLYCOL AND MAGNETIC RESONANCE IMAGE PICK-UP METHOD - An object of the invention is to provide a technique that is safe and quantitative, and is capable of continuously acquiring a magnetic resonance image with a short repetition time. | 06-25-2009 |
| 20090142783 | Human p51 Genes and Gene Products Thereof - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1. | 06-04-2009 |
| 20090082575 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE - The present invention provides a process for production of 2-chloro-4-nitroimidazole in a high yield and at a high purity by a simple operation in a safer manner involving a low risk of explosion or the like. The present invention provides a process for production of 2-chloro-4-nitroimidazole represented by the formula (1): comprising a reaction of a 1-alkoxyalkyl-2-bromo-4-nitroimidazole compound represented by the general formula (7): wherein R1 represents a lower alkyl group, and n represents an integer of 1 to 3, with hydrogen chloride. | 03-26-2009 |
| 20090081790 | Polynucleotide for Target Gene - The present invention provides a single strand polynucleotide sequence comprising a target gene, a complementary strand nucleic acid sequence, and a component sequence. | 03-26-2009 |
| 20090048350 | GASTROINTESTINAL ABSORPTION ENHANCER MEDIATED BY PROTON-COUPLED TRANSPORTER AND ITS PREPARING METHOD - The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell. | 02-19-2009 |
| 20090047357 | METHOD OF PRODUCING DRUG-CONTAINING WAX MATRIX PARTICLES, EXTRUDER TO BE USED IN THE METHOD AND SUSTAINED-RELEASE PREPARATION CONTAINING CILOSTAZOL - The present invention aims to provide a method for producing, by a simple method, drug-containing wax matrix granules, particularly drug-containing wax matrix granules having an average particle diameter of 1 mm or lower, while avoiding liquid blockage due to the recrystallization of a molten drug during the period from a melting step to a spray step. | 02-19-2009 |
| 20080275218 | LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 11-06-2008 |
| 20080268489 | Calcium Ion Leakage Inhibitors - A polypeptide exhibiting the effect of inhibiting Ca | 10-30-2008 |
| 20080260878 | Composition for Prevention or Alleviation of Pigmentation - A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with (B) at least one member selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinols, linoleic acid, tranexamic acid, salts of these, Chamomilla recuita extract, and Ubiquinone. | 10-23-2008 |
| 20080221084 | METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR - The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and/or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder. | 09-11-2008 |
| 20080199859 | Identification Marker Responsive to Interferon Therapy for Renal Cell Cancer - The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator. | 08-21-2008 |
